The nation of Zimbabwe has declined a substantial American health deal valued at 367 million US dollars (272 million pounds) spanning five years due to the United States' insistence on confidential data.
This rejection came to light following a internal memorandum dated December was disclosed, revealing that President Emmerson Mnangagwa deemed the arrangement was "lopsided".
An official spokesperson has since clarified that the United States was seeking biological samples for scientific study and commercial purposes but refused to share the benefits from any future medical innovations.
"We are forced to start the challenging and unfortunate task of ending our health aid in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the United States had furnished more than $1.9bn for health programmes to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has urged further talks to reach a deal acceptable to both sides so the country's critical HIV programme can proceed.
Wider Background
This rejection follows a similar case in Kenya, where a high court blocked a similar health funding agreement following legal challenges were raised about the security of Kenyans' health data.
Since returning to office last year, US President Donald Trump has slashed overseas assistance and closed the US Agency for International Development (USAID).
USAID had overseen assistance for the US government, but Trump stated its expenditure was "inefficient" and his administration was seeking direct bilateral agreements to boost transparency and responsibility.
According to reports, Sixteen African countries have to date signed similar health pacts, constituting over $18.3bn in committed funds.
Details of the Declined Deal
This assistance for Zimbabwe would have supported "combating HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We are confident this partnership would have delivered extraordinary advantages for Zimbabwean communities, particularly the 1.2 million men, women and children presently receiving HIV treatment via American-funded programmes," the Ambassador commented.
However, official spokesman Nick Mangwana maintained the arrangement was "unfair".
"Zimbabwe was being asked to share its biological resources and data for a long time, with no corresponding guarantee of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could result from that shared data," he stated.
"In essence, our nation would supply the raw materials for scientific discovery without any certainty that the end products would be accessible to our population if a future pandemic emerge."
National Interest and International Frameworks
He also noted that the US's withdrawal from the World Health Organization (WHO) and its push of bilateral health agreements were upending frameworks previously established via the global organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing scheme created to deal with future pandemics.
"This mechanism is designed to guarantee that when a country provides its information, the resulting advantages – such as medicines and cures – are distributed fairly, not monopolised solely by those with the funds to create them."
These objections over the US deal "should not be misconstrued as opposition to America," he added.
"We encourage further discussions with our US partners on how subsequent collaboration could be designed in a way that respects the sovereignty and interests of both nations."
Medical Community Response
Medical experts stated it understood the official position, but suggested that negotiations must proceed given that much of the country's Aids initiatives depended on international support.
"If technical issues exist, such as those involving information security or agreement terms, these can frequently be addressed through technical clarification and negotiated safeguards," it said.
This impasse highlights the continuing debate between receiving much-needed foreign assistance and safeguarding a country's data in an increasingly interconnected world.